Claim Missing Document
Check
Articles

Found 3 Documents
Search

Mesenchymal Stem Cell in 3D Culture: Diminishing Cell Senescence in Cryopreservation and Long-term Expansion Jundan, Sheila Fawziyya; Amalia, Riezki; Sartika, Cynthia Retna
Molecular and Cellular Biomedical Sciences Vol 7, No 3 (2023)
Publisher : Cell and BioPharmaceutical Institute

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21705/mcbs.v7i3.360

Abstract

Mesenchymal stem cells (MSCs) are widely recognized in cell treatment due to their capacity to secrete trophic factors, differentiate multipotent, and self-renew. Although there is growing evidence that MSCs have therapeutic benefits in various clinical settings, these cells eventually lose their ability to regenerate as they age, which increases cellular dysfunction. Several factors may affect MSCs aging, such as culture dimensions, cryopreservation process, and long-term expansion. Traditional two-dimensional (2D) culture conditions lack the complexities required to recreate MSCs in their natural environment. Meanwhile, three-dimensional (3D) culture mimics the niche, dynamic, and specialized microenvironments of the cells in vivo. The most used storage technique for MSCs, cryopreservation, requires a very low temperature reduction, which stresses cells and can cause the release of pro-inflammatory cytokines. For the utilization of MSCs in therapeutic applications, an in vitro expansion technique is required. Repeated expansion may reduce proliferative capacity, disrupts cellular shape, and impairs the somatic cell function of MSCs. Various processes and techniques may influence MSCs leading to cell aging. One of the culture methods, 3D culture, is shown to reduce the factors that will compromise the therapeutic effects of MSCs, especially cell senescence. The effect of culture dimensions, cryopreservation, and long-term expansion on cell senescence will be discussed in this review article.Keywords: cell aging, mesenchymal stem cell, 3D culture, cell senescence, cryopreservation, long-term expansion
Potency of Peripheral Blood- and Umbilical Cord Blood-derived Dendritic Cells and Their Secretomes as Vaccines for Cancer Haifa, Rima; Sartika, Cynthia Retna; Faried, Ahmad; Hadisaputri, Yuni Elsa; Chouw, Angliana; Wijaya, Andi; Barliana, Melisa Intan
Molecular and Cellular Biomedical Sciences Vol 8, No 1 (2024)
Publisher : Cell and BioPharmaceutical Institute

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21705/mcbs.v8i1.358

Abstract

Dendritic cell (DC) vaccines, as immunotherapy agents, can gather up and transport cancer-related antigens to T lymphocytes, activating anti-tumor effector responses. After being activated by DC, cytotoxic T lymphocyte cells (CTL) will secrete the cytolytic granzyme B that can effectively induce rapid apoptosis of target cells. On the other hand, DC also secrete several cytokines and a large number of exosomes, which together operate as a whole antigen-presenting entity. The efficacy of the vaccine’s treatment may be affected by the sources used for DC vaccines. Umbilical cord blood (UCB) from healthy donors can be employed when autologous cancer patient’s peripheral blood (PB) cannot be used as a source for isolating DC due to genetic abnormalities. Comparing UCB to other sources, there is a painless method of collecting sources as opposed to PB, which necessitates a venipuncture or leukapheresis procedure to isolate the blood. Many studies related to the use of PB-DC have been carried out, but research on potential comparisons between PB-DC and UCB-DC is still very limited. In this review, the potential of PB- and UCB-derived DC and their secretomes for cancer will be discussed.Keywords: dendritic cells, vaccines, umbilical cord blood, peripheral blood
In vitro Production of Dendritic Cells as Cancer Immunotherapy: Highlights on Sample Source, Culture Period, Differentiation and Maturation Cytokines Facicilia, Geofanny; Sartika, Cynthia Retna; Rostinawati, Tina
Molecular and Cellular Biomedical Sciences Vol 7, No 3 (2023)
Publisher : Cell and BioPharmaceutical Institute

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21705/mcbs.v7i3.357

Abstract

Dendritic cells (DC) are antigen-presenting cells between innate and adaptive immune cells and commonly used as immunotherapy. Despite this promising potential, protocols detailing the specifics of the DC production are varied, affecting the potency of dendritic as immunotherapy. There are various factors affecting the production and DC potency, such as sample source, culture period, differentiation and maturation cytokines. Due to the limited number and quality of DC in humans, the monocyte could be isolated and differentiated to mature DC. The purity and viability monocytes shall be maintained to produce a high yield of DC. Negative sorting maintains the potency of DC as a therapeutic agent. Monocytes from umbilical cord blood (UCB) are naïve and can be differentiated to DC easily. Meanwhile, the tumor microenvironment (TME) may inhibit DC maturation from monocyte-derived peripheral blood. Without pro-inflammatory cytokines and a short maturation period, DC remain immature and fails to activate T cells. Long-period culture correlates with decreased DC viability and function. This review outlines several factors which can produce higher cytotoxic T cells and pro-inflammatory cytokines that might help each facility in developing its protocol to ensure the best procedure in DC production. Increasing purity and yield through close and automatic system under GMP production are mandatory to decrease risk of contamination during DC production.Keywords: differentiation cytokines, maturation cytokines, culture period, sample source, isolation technique